Background: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved by the US Food and Drug Administration as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. In addition to TG-lowering effects, IPE also reduces non-high-density lipoprotein cholesterol and apolipoprotein B levels without significantly increasing low-density lipoprotein cholesterol (LDL-C) in patients with very high TG levels ≥500 mg/dL (MARINE study) and in patients with well-controlled LDL-C and residually high TG levels 200-500 mg/dL (ANCHOR study). This analysis examined the effect of IPE on inflammatory markers in patients from MARINE and ANCHOR.
Methods: MARINE (N = 229) and ANCHOR (N = 702) were Phase III, double-blind studies that randomized hypertriglyceridemic patients to IPE 4 g/day, 2 g/day, or placebo. This analysis assessed the median placebo-adjusted percentage change from baseline in markers representing various stages of atherosclerotic inflammation such as intercellular adhesion molecule-1 (ICAM-1), oxidized low-density lipoprotein (Ox-LDL), lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP).
Results: Compared to placebo, IPE 4 g/day significantly decreased Ox-LDL (13 %, p < 0.0001, ANCHOR), Lp-PLA(2) (14 %, p < 0.001, MARINE; 19 %, p < 0.0001, ANCHOR), and hsCRP levels (36 %, p < 0.01, MARINE; 22 %, p < 0.001, ANCHOR), but did not significantly change ICAM-1 and IL-6 levels. In the MARINE study, IPE 2 g/day did not significantly change ICAM-1, Ox-LDL, Lp-PLA(2), IL-6, or hsCRP levels. Also, compared to placebo in the ANCHOR study, IPE 2 g/day significantly decreased Lp-PLA(2) levels (8 %, p < 0.0001), but did not significantly change levels of other assessed inflammatory markers.
Conclusion: Compared to placebo, in hypertriglyceridemic patients, IPE 4 g/day significantly decreased Ox-LDL, Lp-PLA(2), and hsCRP levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572383 | PMC |
| http://dx.doi.org/10.1007/s40256-012-0002-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
Med
July 2024
Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada. Electronic address:
Article Synopsis
- - REDUCE-IT trial showed icosapent ethyl (IPE) decreased major cardiovascular events by 25%, but the exact reasons for its benefits were unclear, leading to the IPE-PREVENTION CardioLink-14 trial to explore its effect on vascular regenerative (VR) cell content in individuals with high triglycerides.
- - In the study, 70 individuals on statins were given either IPE (4 g/day) or usual care; results showed IPE increased the frequency of ALDHSSC CD133 progenitor cells and reduced oxidative stress in progenitor cells, even as overall ALDHSSC cell frequency decreased.
- - The findings suggest that IPE not only impacts VR cell content but may also
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
Eur Heart J Open
November 2023
Department of Medicine, Baylor College of Medicine, Texas Heart Institute, Houston, TX, USA.
Article Synopsis
- Metabolic syndrome (MetSyn) significantly increases the risk of cardiovascular (CV) events, but icosapent ethyl (IPE) has shown promise in reducing this risk even in statin-treated patients. !* -
- The REDUCE-IT trial involved 8179 high-risk patients with controlled LDL cholesterol and high triglycerides, finding that those with MetSyn but no diabetes had a 29% lower risk of serious CV events when taking IPE. !* -
- Overall, IPE was associated with major reductions in various CV-related risks, making it a potentially valuable addition for managing patients with MetSyn who are already on statin therapy. !*
Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE.
Front Cardiovasc Med
August 2023
Department of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, United States.
Article Synopsis
- - The study, EVAPORATE, aimed to assess the impact of icosapent ethyl (IPE) on coronary plaque characteristics in patients already on statin therapy, focusing on individual-level changes rather than just overall group results.
- - A total of 55 patients were randomized to receive either IPE or a placebo, with plaque morphology analyzed through advanced imaging techniques that measured factors like lipid-rich necrotic core size and fibrous cap thickness at 9 and 18 months.
- - Results showed that patients taking IPE experienced a significant reduction in lipid-rich necrotic core size compared to placebo, indicating potential benefits in plaque stability, while additional changes in wall and cap thickness suggested a more complex, individualized response to treatment
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.
Lipids Health Dis
June 2023
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Article Synopsis
- The study investigated the safety and effectiveness of icosapent ethyl (IPE) in treating very high triglyceride (TG) levels in a Chinese population as part of a phase III clinical trial.
- Patients with TG levels between 5.6-22.6 mmol/L were randomly assigned to receive either 4 g or 2 g of IPE daily, or a placebo, with assessments made after 12 weeks.
- Results showed that 4 g/day of IPE significantly reduced TG levels by about 28.4%, along with notable decreases in harmful cholesterol levels, and was well tolerated without raising LDL-C levels.
Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review.
Cureus
December 2022
General Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Despite the widespread use of lipid-lowering agents such as statins, cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Icosapent ethyl (IPE) (Vascepa), an ethyl ester of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA), has gained widespread popularity as an adjunctive agent that targets multiple and additional mechanisms linked to the incidence of cardiovascular (CV) events and the causative pathway of atherosclerosis. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 standards were used to conduct this systematic review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!